Literature DB >> 30341009

Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer.

Maria Rovira-Rigau1, Giulia Raimondi1, Miguel Ángel Marín2, Meritxell Gironella3, Ramon Alemany4, Cristina Fillat5.   

Abstract

Oncolytic viruses are designed for cancer treatment. Cell-virus interactions are key determinants for successful viral replication. Therefore, the extensive reprogramming of gene expression that occurs in tumor cells might create a hurdle for viral propagation. We used a replication-based approach of a microRNA (miRNA) adenoviral library encoding up to 243 human miRNAs as a bioselection strategy to identify miRNAs that facilitate adenoviral oncolytic activity in pancreatic ductal adenocarcinoma. We identify two miRNAs, miR-99b and miR-485, that function as enhancers of adenoviral oncolysis by improving the intra- and extracellular yield of mature virions. An increased adenoviral activity is the consequence of enhanced E1A and late viral protein expression, which is probably mediated by the downregulation of the transcriptional repressors ELF4, MDM2, and KLF8, which we identify as miR-99b or miR-485 target genes. Arming the oncolytic adenovirus ICOVIR15 with miR-99b or miR-485 enhances its fitness and its antitumoral activity. Our results demonstrate the potential of this strategy to improve oncolytic adenovirus potency, and they highlight miR-99b and miR-485 as sensitizers of adenoviral replication.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  miRNAs; oncolytic adenovirus; pancreatic cancer

Mesh:

Substances:

Year:  2018        PMID: 30341009      PMCID: PMC6318784          DOI: 10.1016/j.ymthe.2018.09.016

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  51 in total

1.  Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer.

Authors:  L-L Jing; X-M Mo
Journal:  Eur Rev Med Pharmacol Sci       Date:  2016-04       Impact factor: 3.507

2.  Krüppel-like factor 8 induces epithelial-to-mesenchymal transition and promotes invasion of pancreatic cancer cells through transcriptional activation of four and a half LIM-only protein 2.

Authors:  Xiaoping Yi; Hongyan Zai; Xueying Long; Xiaoyi Wang; Wenzheng Li; Yixiong Li
Journal:  Oncol Lett       Date:  2017-08-09       Impact factor: 2.967

3.  Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2.

Authors:  Victor W van Beusechem; Petra B van den Doel; Winald R Gerritsen
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

4.  The microRNA-99 family modulates hepatitis B virus replication by promoting IGF-1R/PI3K/Akt/mTOR/ULK1 signaling-induced autophagy.

Authors:  Yong Lin; Wanyu Deng; Jinke Pang; Thekla Kemper; Jing Hu; Jian Yin; Jiming Zhang; Mengji Lu
Journal:  Cell Microbiol       Date:  2017-01-05       Impact factor: 3.715

5.  miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator.

Authors:  Dimitrios Lagos; Gabriel Pollara; Stephen Henderson; Fiona Gratrix; Martin Fabani; Richard S B Milne; Frances Gotch; Chris Boshoff
Journal:  Nat Cell Biol       Date:  2010-04-25       Impact factor: 28.824

Review 6.  Recent advances in oncolytic adenovirus therapies for cancer.

Authors:  Amanda Rosewell Shaw; Masataka Suzuki
Journal:  Curr Opin Virol       Date:  2016-07-02       Impact factor: 7.090

7.  KLF8 recruits the p300 and PCAF co-activators to its amino terminal activation domain to activate transcription.

Authors:  Alison M Urvalek; Xianhui Wang; Heng Lu; Jihe Zhao
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

Review 8.  Stealing the Keys to the Kitchen: Viral Manipulation of the Host Cell Metabolic Network.

Authors:  Christopher M Goodwin; Shihao Xu; Joshua Munger
Journal:  Trends Microbiol       Date:  2015-10-01       Impact factor: 17.079

9.  MicroRNAs for Detection of Pancreatic Neoplasia: Biomarker Discovery by Next-generation Sequencing and Validation in 2 Independent Cohorts.

Authors:  Elena Vila-Navarro; Maria Vila-Casadesús; Leticia Moreira; Saray Duran-Sanchon; Rupal Sinha; Àngels Ginés; Glòria Fernández-Esparrach; Rosa Miquel; Miriam Cuatrecasas; Antoni Castells; Juan José Lozano; Meritxell Gironella
Journal:  Ann Surg       Date:  2017-06       Impact factor: 12.969

Review 10.  Implications of MicroRNAs in Oncolytic Virotherapy.

Authors:  Xavier Bofill-De Ros; Maria Rovira-Rigau; Cristina Fillat
Journal:  Front Oncol       Date:  2017-07-04       Impact factor: 6.244

View more
  9 in total

Review 1.  An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer.

Authors:  Maryum Nisar; Rehan Zafar Paracha; Sidra Adil; Sumair Naseem Qureshi; Hussnain Ahmed Janjua
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

2.  MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells.

Authors:  Ying Liang; Wen-Yu Tian; Juan-Juan Huang; Ling-Xi Gao; Xiao-Hui Fan
Journal:  Oncol Lett       Date:  2021-04-21       Impact factor: 2.967

Review 3.  Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses.

Authors:  Martí Farrera-Sal; Cristina Fillat; Ramon Alemany
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

4.  Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.

Authors:  Marie-Eve Wedge; Victoria A Jennings; Mathieu J F Crupi; Joanna Poutou; Taylor Jamieson; Adrian Pelin; Giuseppe Pugliese; Christiano Tanese de Souza; Julia Petryk; Brian J Laight; Meaghan Boileau; Zaid Taha; Nouf Alluqmani; Hayley E McKay; Larissa Pikor; Sarwat Tahsin Khan; Taha Azad; Reza Rezaei; Bradley Austin; Xiaohong He; David Mansfield; Elaine Rose; Emily E F Brown; Natalie Crawford; Almohanad Alkayyal; Abera Surendran; Ragunath Singaravelu; Dominic G Roy; Gemma Migneco; Benjamin McSweeney; Mary Lynn Cottee; Egon J Jacobus; Brian A Keller; Takafumi N Yamaguchi; Paul C Boutros; Michele Geoffrion; Katey J Rayner; Avijit Chatterjee; Rebecca C Auer; Jean-Simon Diallo; Derrick Gibbings; Benjamin R tenOever; Alan Melcher; John C Bell; Carolina S Ilkow
Journal:  Nat Commun       Date:  2022-04-07       Impact factor: 17.694

Review 5.  Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer.

Authors:  Wenhao Luo; Yawen Wang; Taiping Zhang
Journal:  Cancer Cell Int       Date:  2022-04-20       Impact factor: 6.429

6.  Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.

Authors:  Giulia Raimondi; Ana Mato-Berciano; Silvia Pascual-Sabater; Maria Rovira-Rigau; Miriam Cuatrecasas; Constantino Fondevila; Santiago Sánchez-Cabús; Harry Begthel; Sylvia F Boj; Hans Clevers; Cristina Fillat
Journal:  EBioMedicine       Date:  2020-05-24       Impact factor: 8.143

7.  Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control.

Authors:  Ting-Miao Wu; Ji-Bin Liu; Yu Liu; Yi Shi; Wen Li; Gao-Ren Wang; Yu-Shui Ma; Da Fu
Journal:  Cancer Control       Date:  2020 Jul-Aug       Impact factor: 3.302

Review 8.  Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions.

Authors:  Molly C Holbrook; Dakota W Goad; Valery Z Grdzelishvili
Journal:  Cancers (Basel)       Date:  2021-03-09       Impact factor: 6.639

9.  Preclinical testing of oncolytic adenovirus sensitivity in patient-derived tumor organoids.

Authors:  Silvia Pascual-Sabater; Giulia Raimondi; Ana Mato-Berciano; Eva C Vaquero; Fabio Ausania; Cristina Fillat
Journal:  STAR Protoc       Date:  2021-12-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.